A Very Successful 2018 at Nanoview Biosciences

Jerry Williamson appointed Chief Executive Officer - July 2018

"The markets for exosome detection and characterization are exploding and NanoView has the opportunity to rapidly emerge as a leading

technology provider for basic research and therapeutic and diagnostic development."  Exciting words from Jerry Williamson who took the helm as CEO of Nanoview on July 1st. Mr Williamson has worked in life sciences arena for more than 30 years, a key player within companies specialising in such fields as genomic profiling and molecular diagnostics. His corporate roles have been primarily in business development and commercial operations. He succeeded Dr David Freedman, one of Nanoview's co-founders. 

Grant awarded from the National Science Foundation - September 2018

The National Science Foundation (SBIR), the agency that supports fundamental research and education across all fields of science and engineering awarded Nanoview Biosciences a Phase II grant of $750,000. With the aim of solving the problems that current research methods have trying to effectively identify and characterise exosomes, the funds will be used to further enhance the completed Phase I research and development of our innovative ExoView™ system, advancing the platform and preparing for its commercialization. 

NanoView Biosciences